CheckMate 743 Shows That Dual Immunotherapy, Nivolumab + Ipilimumab, Improves Overall Survival for Patients with Previously Untreated Mesothelioma
DENVER, Aug. 08, 2020 (GLOBE NEWSWIRE) -- The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy.
The study is presented by Paul Baas, M.D., from The Netherlands Cancer Institute and The University of Leiden, in Amsterdam. Watch a video of Dr. Baas explaining his research here: https://vimeo.com/443190432/32a40271f0
Nivolumab is an immunotherapy that works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer. Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. When administered in combination, this dual immunotherapy has shown clinical benefit in 6 different tumor types, including mesothelioma.
In this large phase III study, Dr. Baas and the global study investigators randomly assigned more than 600 patients: 303 to the nivolumab + ipilimumab arm and 302 to the chemotherapy arm. The study had a minimal follow up of close to two years. Two-year overall survival rates were 40.8% for the patients in the experimental treatment arm vs 27.0% in chemotherapy arm. Of the 30.3% of patients in the study-combination group who experienced grade 3-4 adverse events, 15% discontinued therapy compared with 7.4% of the 32.0% of patients in chemotherapy group.
CheckMate 743 met its primary endpoint of statistically improved OS with nivolumab + ipilimumab vs standard of care chemotherapy in first-line treatment of patients with mesothelioma, said Dr. Baas. These clinically meaningful data represent the first positive phase 3 trial of immunotherapy in first-line MPM and should be considered as a new standard of care.
Phase 3 eXalt3 Study Shows Significantly Longer Progression-Free Survival in Patients with ALK+ Lung Cancer with Ensartinib Versus Crizotinib
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib.
The results were presented today by Leora Horn, MD, Ingram Associate Professor of Cancer Research in the Division of Hematology/Oncology and director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, Nashville, Tenn. View a video interview of Dr. Horn discussing the trial here: https://vimeo.com/444703327/6ad043dd00.
Ensartinib (X-396) is a novel next-generation ALK tyrosine kinase inhibitor (TKI). According to Dr. Horn, in Phase 1 and 2 studies, ensartinib showed promising activity in patients with ALK+ NSCLC who were ALK TKI treatment naive or received prior crizotinib or second-generation ALK TKIs, including strong activity in patients with brain metastases.
Crizotinib is an anti-cancer drug acting as an ALK, MET, and ROS1 inhibitor, approved for treatment of some subtypes of patients with NSCLC (including ALK+) in the United States and other countries worldwide.
Dr. Horn and her colleagues at the participating cancer centers randomized 290 patients with ALK+ NSCLC to either ensartinib or crizotinibthe prespecified intent to treat (ITT) population with locally determined ALK+ NSCLC. Patients were stratified by prior chemotherapy, Eastern Cooperative Oncology Group performance status, brain metastases, and geographic region. Baseline characteristics were well balanced between the two groups: median age was 54.1; 26% of patients had prior chemotherapy, and 36% of patients had baseline brain metastases (5% had prior brain radiotherapy). The modified ITT population (the prespecified patient population that was ALK+ as confirmed by central Abbott FISH test) included 247 patients, of which 121 received ensartinib and 126 received crizotinib.
At the July 1, 2020 data cutoff, based on a pre-planned interim analysis design (at 75% of progression-free survival events) treatment was ongoing in 64 ensartinib-treated patients (45%) and 25 crizotinib-treated patients (17%). There were 139 patients who experienced disease progression (as assessed by blinded independent review committee, BIRC) or death, which represented 73% of progression events in the ITT population and 119 BIRC-events or deaths (63%) in the mITT population.
According to Dr. Horn, the trials analysis demonstrated a statistically significant difference between patients who received ensartinib, with a median progression-free survival of 25.8 months compared with 12.7 months with crizotinib, with a median follow-up of 23.8 and 20.2 months, respectively (HR, 0.52; 95% CI, 0.36-0.75; P=.0003 by log-rank test). In the mITT population, the median progression-free survival has not been reached yet for the ensartinib arm vs. 12.7 months for the crizotinib arm (HR, 0.48; 95% CI, 0.32-0.71; P=.0002 by log-rank test).
The overall response rate was 75% versus 67% with crizotinib; among patients with measurable brain metastases, the BIRC-assessed intracranial overall response rate was 64% with ensartinib versus 21% with crizotinib.
The time-to-treatment-failure rate in the brain in patients with no baseline brain metastases was also significantly lower with ensartinib compared to crizotinib (4% vs 24% at 12 months).
In patients with ALK-positive NSCLC, ensartinib significantly prolonged progression-free survival over crizotinib with a favorable safety profile, representing a new option in the first-line setting, Dr. Horn concluded.
Addition of Sintilimab to Pemetrexed and Platinum Improved Progression-Free Survival in Patients with Nonsquamous Non-Small Cell Lung CancerResults of ORIENT-11 Presented at IASLC Virtual Presidential Symposium
The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.
The research findings are also published simultaneously in the Journal of Thoracic Oncology, the journal of the International Association for the Study of Lung Cancer.
Previously, sintilimab in combination with pemetrexed and a platinum-based chemotherapy had shown promising activity for nonsquamous non small cell lung cancer in a phase 1b study, according to Li Zhang, M.D., of Sun Yat-sen University Cancer Center, Guangzhou, China.
Dr. Zhang and investigators from centers in China enrolled 397 patients in the study. Of these, 266 and 131 patients were randomly assigned to the sintilimab combination and to placebo combination, respectively. Patients with all ranges of PD-L1 expression (by tumor proportion score, TPS) were included. The median progression free survival per was significantly improved in sintilimab-combination group compared to placebo combination group (8.9 vs. 5.0 months).
Dr. Zhang reported that sintilimab-combination group showed a nominally significant improvement of overall survival The overall response rate also was improved for the sintilimab-combination group (51.9% versus 29%). The safety signal for the sintilimab combination was similar to that found in other studies, but rates of occurrence of grade > 3 adverse events were slightly higher in the sintilimab-combination group (61.7% versus 58.8%).
This study demonstrated that the addition of sintilimab to chemotherapy significantly improved progression-free survival and a nominally improved overall survival, with an acceptable safety profile in [patients with] first-line non-squamous non small cell lung cancer, said Dr. Zhang. In this study, we collected tumor samples at baseline of treatment. So, our next work will focus on biomarker exploration. By RNA sequencing of tumor samples, we look forward to searching a potential biomarker which can predict the survival benefit from PD-1 combination with chemotherapy.
For more information, visit https://www.iaslc.org/Conferences-Events/Event-Details/iaslc-wclc-2020-singapore-virtual-presidential-symposium
Chris Martin CMartin@DavidJamesGroup.com | 630-670-2745
Read more:
- Diagnosing Pleural Mesothelioma with Lung Fluid: The Battle of the Biomarkers - Surviving Mesothelioma - March 24th, 2017 [March 24th, 2017]
- Republican Health Care Bill Includes Asbestos Exposure Funding for Libby Residents - Mesothelioma.com - March 24th, 2017 [March 24th, 2017]
- Pembrolizumab shows promise in treatment of mesothelioma - Science Daily - March 24th, 2017 [March 24th, 2017]
- Veterans with Mesothelioma Benefit from Telephone Triage - Asbestos.com - March 24th, 2017 [March 24th, 2017]
- Mesothelioma Survival Rates Slowly Improving - Mesothelioma.net Blog (blog) - March 24th, 2017 [March 24th, 2017]
- Understanding Mesothelioma Caregiver Styles - Asbestos.com (blog) - March 24th, 2017 [March 24th, 2017]
- Mesothelioma Patients Turn to Cannabis - AlterNet - March 24th, 2017 [March 24th, 2017]
- Mesothelioma | Overview, Treatment Options and Survivor Stories - March 24th, 2017 [March 24th, 2017]
- Accelerated Approval Granted to Drug in Mesothelioma Research Pipeline - MesotheliomaHelp.org (blog) - April 8th, 2017 [April 8th, 2017]
- New Study Affirms Mesothelioma Survival Benefit with Post-Surgical IMRT, According to Surviving Mesothelioma - Benzinga - April 8th, 2017 [April 8th, 2017]
- The Key to Mesothelioma Treatment Success with Immunotherapy - Surviving Mesothelioma - April 8th, 2017 [April 8th, 2017]
- New Evidence Supports Post-Surgical IMRT for Mesothelioma Treatment - Surviving Mesothelioma - April 8th, 2017 [April 8th, 2017]
- Shorter Mesothelioma Survival Linked to High Platelet Count - Asbestos.com - April 8th, 2017 [April 8th, 2017]
- Mesothelioma Victims Center Now Appeals to All Diagnosed ... - Yahoo Finance - April 8th, 2017 [April 8th, 2017]
- Early research suggests first immunotherapy for mesothelioma on the horizon - Medical Xpress - June 6th, 2017 [June 6th, 2017]
- Bristol-Myers Squibb's Opdivo, Yervoy put the brakes on mesothelioma in phase 2 - FiercePharma - June 6th, 2017 [June 6th, 2017]
- Methanol from African Plants Kills Mesothelioma Cells - Asbestos.com - June 6th, 2017 [June 6th, 2017]
- Mesothelioma Patients to be Celebrated on National Cancer Survivor's Day - Mesothelioma.net Blog (blog) - June 6th, 2017 [June 6th, 2017]
- IO Strategy In Mesothelioma Finally Gets Mapped Out | Seeking Alpha - Seeking Alpha - June 6th, 2017 [June 6th, 2017]
- New Blood Test Could Mean Earlier Mesothelioma Diagnosis - Surviving Mesothelioma - June 6th, 2017 [June 6th, 2017]
- Using Viruses to Boost Mesothelioma Immunotherapy - Asbestos.com - June 6th, 2017 [June 6th, 2017]
- Resilience Can Help Mesothelioma Patients and Their Families ... - MesotheliomaHelp.org (blog) - June 7th, 2017 [June 7th, 2017]
- Janet Stanton Schnitzer Remembers Her Father's Mesothelioma Battle - Mesothelioma & Asbestos Awareness Center (blog) - June 7th, 2017 [June 7th, 2017]
- Treating Mesothelioma: A rare, aggressive caner - ABC2 News - June 7th, 2017 [June 7th, 2017]
- Asbestos and Mesothelioma Lawsuits: What to Expect | Nolo.com - June 7th, 2017 [June 7th, 2017]
- Mesothelioma Victims Center Now Urges a Roofer/Insulator With Mesothelioma to Call About Why It Is Necessary to ... - PR Newswire (press release) - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Patients May Have Another Treatment Option With FDA Expanded-Use Approval of Lung Cancer Drug - MesotheliomaHelp.org (blog) - June 9th, 2017 [June 9th, 2017]
- A Breath Test for Mesothelioma? - Surviving Mesothelioma - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Cancer: 12 Essential Facts - Asbestos News - June 9th, 2017 [June 9th, 2017]
- Mesothelioma - NHS Choices - June 9th, 2017 [June 9th, 2017]
- 15-year Mesothelioma Survivor Living Life By Design - Asbestos.com (blog) - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Cancer Overview | Experienced Lawyers Here to Help - June 11th, 2017 [June 11th, 2017]
- Mesothelioma Victims Center Now Urges a Diagnosed Machinist to Call for Direct Access to Journeyman-Level ... - PR Newswire (press release) - June 12th, 2017 [June 12th, 2017]
- Honeywell Fails in Appeal Against Mesothelioma Verdict - Mesothelioma.net Blog (blog) - June 12th, 2017 [June 12th, 2017]
- Mesothelioma Patients Can See Improved Survival By Reporting Side Effects - MesotheliomaHelp.org (blog) - June 12th, 2017 [June 12th, 2017]
- What is Mesothelioma? | Surviving Mesothelioma - Surviving Mesothelioma - June 13th, 2017 [June 13th, 2017]
- Cases of Pleural Mesothelioma - Surviving Mesothelioma - June 13th, 2017 [June 13th, 2017]
- The Importance of Cancer Research in Immunotherapy - Mesothelioma.com (blog) - June 14th, 2017 [June 14th, 2017]
- Hopes High for Mesothelioma Immunotherapy Treatment ... - Mesothelioma.net Blog (blog) - June 14th, 2017 [June 14th, 2017]
- Asbestos Sprayers Face Higher Lifetime Mesothelioma Risk ... - Surviving Mesothelioma - June 14th, 2017 [June 14th, 2017]
- Remembering Loved Ones Lost to Mesothelioma, Looking Forward to Progress in Treatment - MesotheliomaHelp.org (blog) - June 14th, 2017 [June 14th, 2017]
- Chicago Public Schools Ignoring Asbestos Problem - Mesothelioma.com - June 16th, 2017 [June 16th, 2017]
- Length of Time Between Surgeries a Marker for Mesothelioma Survival - Surviving Mesothelioma - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Survivor Deals with Pain 15 Years After Surgery - Asbestos.com (blog) - June 16th, 2017 [June 16th, 2017]
- Nivolumab and Ipillimumab Show Promise in Treating Mesothelioma Recurrence - Mesothelioma.com - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Patients Should Heed FDA Warnings Regarding Miracle Cures - MesotheliomaHelp.org (blog) - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Patients May Benefit from Marijuana Research - Mesothelioma.net Blog (blog) - June 17th, 2017 [June 17th, 2017]
- The Challenges of Research in Immunotherapy - Mesothelioma.com (blog) - June 17th, 2017 [June 17th, 2017]
- Despite Mesothelioma Diagnosis, Dad Loved Father's Day - Asbestos.com (blog) - June 17th, 2017 [June 17th, 2017]
- I Want to Keep Writing About Mesothelioma and My Family's Journey Because It Matters - MesotheliomaHelp.org (blog) - June 17th, 2017 [June 17th, 2017]
- Mesothelioma Clinical Trial Opens with High Expectations - Asbestos.com - June 17th, 2017 [June 17th, 2017]
- Cediranib May be Safe Supplement to Mesothelioma Treatment - Surviving Mesothelioma - June 17th, 2017 [June 17th, 2017]
- New Trial Finds VEGF-Inhibitor May Safely Boost Mesothelioma ... - Benzinga - June 18th, 2017 [June 18th, 2017]
- Mesothelioma Symptoms - Identify Early Warning Signs - June 18th, 2017 [June 18th, 2017]
- Mesothelioma Victims Center Now Urges a Diagnosed Construction Worker or Plumber to Call for Instant Access to the ... - PR Newswire (press release) - June 20th, 2017 [June 20th, 2017]
- Mesothelioma Treatment May Benefit From New Discovery ... - Mesothelioma.net Blog (blog) - June 20th, 2017 [June 20th, 2017]
- The Influence of BAP1 on Mesothelioma Survival - Surviving Mesothelioma - June 20th, 2017 [June 20th, 2017]
- Clinical Trial to Assess If Radiation Therapy Can Bring Effective Relief from Mesothelioma Pain - MesotheliomaHelp.org (blog) - June 20th, 2017 [June 20th, 2017]
- Asbestos Exposure Attorneys - Mesothelioma Lawsuits ... - June 20th, 2017 [June 20th, 2017]
- Can a Breath Test Diagnose Mesothelioma in the Early Stages? - Asbestos.com - June 21st, 2017 [June 21st, 2017]
- Mesothelioma Compensation Center Now Urges an Electric Utility Worker or Electrician with Mesothelioma to Aim High ... - PR Newswire (press release) - June 21st, 2017 [June 21st, 2017]
- Nurse Explains Mesothelioma Staging - MesotheliomaHelp.org (blog) - June 21st, 2017 [June 21st, 2017]
- 5 Questions: Treatment options exist for mesothelioma - Las Vegas Review-Journal - June 21st, 2017 [June 21st, 2017]
- Steve McQueen's Wife Pushes for Asbestos Ban - Mesothelioma.com - June 21st, 2017 [June 21st, 2017]
- Remembering Mesothelioma Victims in the UK - Mesothelioma.com (blog) - June 21st, 2017 [June 21st, 2017]
- Peritoneal Cancer Index: What it Means for Mesothelioma Patients - Mesothelioma & Asbestos Awareness Center (blog) - June 21st, 2017 [June 21st, 2017]
- Mesothelioma Risk Continues to Rise for Decades After Asbestos Exposure - Surviving Mesothelioma - June 21st, 2017 [June 21st, 2017]
- Nintedanib Combination Delayed Progression in Malignant Mesothelioma - Cancer Network - June 22nd, 2017 [June 22nd, 2017]
- Polish Study Confirms That Mesothelioma Risk Only Increases With ... - Mesothelioma.net Blog (blog) - June 22nd, 2017 [June 22nd, 2017]
- The Mesothelioma Victims Center Now Urges a Diagnosed Navy ... - PR Newswire (press release) - June 22nd, 2017 [June 22nd, 2017]
- Targeted Therapy May Soon be Primary Approach for Mesothelioma Treatment - MesotheliomaHelp.org (blog) - June 23rd, 2017 [June 23rd, 2017]
- Time Between Surgeries Helps Predict Mesothelioma Survival - Asbestos.com - June 23rd, 2017 [June 23rd, 2017]
- Testicular and Cardiac Mesothelioma - Surviving Mesothelioma - June 23rd, 2017 [June 23rd, 2017]
- Mesothelioma Veterans Center - Access Benefits & VA Claims - June 23rd, 2017 [June 23rd, 2017]
- Malignant Mesothelioma (Asbestos Cancer) > The Mesothelioma ... - June 23rd, 2017 [June 23rd, 2017]
- Mesothelioma Law Firm | Sokolove Law - June 23rd, 2017 [June 23rd, 2017]
- MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma - Surviving Mesothelioma - June 24th, 2017 [June 24th, 2017]
- Mesothelioma Survival Rate | Factors Affecting Survivorship - June 24th, 2017 [June 24th, 2017]
- Scientists "Turn Off" Tumor-Protecting Protein in New Mesothelioma Study, According to Surviving Mesothelioma - Benzinga - June 26th, 2017 [June 26th, 2017]
- Symptoms of Mesothelioma - Critical Signs to Watch For - June 26th, 2017 [June 26th, 2017]